We used digital measurements of CD8+ T cells at the invasive fronts and PD‐L1 in the tumor‐rich areas, and we used FDA‐approved PharmDx kits for PD‐L1 IHC, the most significant biomarker for immunotherapies targeting the PD‐1/PD‐L1 pathway, in a large GC cohort with full tissue sections of gastric adenocarcinoma to investigate clinicopathological characteristics and their effects on prognosis. The gene discussed is CD8A; the disease is neoplasm.